Home > Publications database > Quality of life, distress, and posttraumatic growth 5 years after colorectal cancer diagnosis according to history of inpatient rehabilitation. > print |
001 | 177926 | ||
005 | 20240229133755.0 | ||
024 | 7 | _ | |a 10.1007/s00432-021-03865-3 |2 doi |
024 | 7 | _ | |a pmid:34874489 |2 pmid |
024 | 7 | _ | |a 0084-5353 |2 ISSN |
024 | 7 | _ | |a 0171-5216 |2 ISSN |
024 | 7 | _ | |a 0943-9382 |2 ISSN |
024 | 7 | _ | |a 1432-1335 |2 ISSN |
024 | 7 | _ | |a altmetric:118339652 |2 altmetric |
037 | _ | _ | |a DKFZ-2021-02948 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Scherer-Trame, Sophie |0 P:(DE-He78)a4307287511137778efe28e651f9f245 |b 0 |e First author |u dkfz |
245 | _ | _ | |a Quality of life, distress, and posttraumatic growth 5 years after colorectal cancer diagnosis according to history of inpatient rehabilitation. |
260 | _ | _ | |a Heidelberg |c 2022 |b Springer |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1665050052_20167 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
500 | _ | _ | |a #EA:C120#LA:C070#LA:C120# / 2022 Nov;148(11):3015-3028 |
520 | _ | _ | |a In Germany, almost every other colorectal cancer (CRC) patient undergoes inpatient cancer rehabilitation (ICR), but research on long-term outcomes is sparse. We aimed to assess health-related quality of life (HRQOL), distress, and posttraumatic growth among former rehabilitants and non-rehabilitants as well as respective differences and to estimate disease-related quality of life deficits in both groups.HRQOL (EORTC-QLQ-C30/CR29), distress (QSC-R10), and posttraumatic growth (PTGI) were assessed according to past ICR in patients 5-year post-CRC-diagnosis in the German DACHS study. Least square mean differences in HRQOL scores and elevated distress levels (QSC-R10 > 14 points) by ICR were estimated by confounder-adjusted linear and logistic regression, respectively. Differences in PTGI scales were tested for statistical significance. EORTC-QLQ-C30 reference scores from population controls were accessed from the LinDE study to estimate disease-related deficits in both treatment groups.49% of the included 1906 CRC survivors had undergone ICR. Rehabilitants reported lower HRQOL scores than non-rehabilitants in several dimensions of the EORTC-QLQ-C30/CR29. Differences were pronounced among younger survivors (< 70 years). In younger survivors, past ICR also predicted elevated distress. However, rehabilitants showed higher posttraumatic growth. When compared to 934 population controls, non-rehabilitants and older rehabilitants reported HRQOL scores (EORTC-QLQ-C30) similar to controls except higher levels of bowel dysfunctions, whereas younger rehabilitants experienced deficits regarding most scales (13/15).Our findings suggest a high disease burden 5 years after diagnosis in particular among younger CRC survivors who had undergone ICR. Observed HRQOL deficits are possibly linked to the initial indication for ICR and rehabilitants may benefit from effective follow-up concepts after ICR. |
536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
650 | _ | 7 | |a Cancer survivorship |2 Other |
650 | _ | 7 | |a Colorectal cancer |2 Other |
650 | _ | 7 | |a Distress |2 Other |
650 | _ | 7 | |a Health-related quality of life |2 Other |
650 | _ | 7 | |a Inpatient rehabilitation |2 Other |
650 | _ | 7 | |a Posttraumatic growth |2 Other |
700 | 1 | _ | |a Jansen, Lina |0 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09 |b 1 |u dkfz |
700 | 1 | _ | |a Koch-Gallenkamp, Lena |0 P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88 |b 2 |u dkfz |
700 | 1 | _ | |a Arndt, Volker |0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0 |b 3 |u dkfz |
700 | 1 | _ | |a Chang-Claude, Jenny |0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |b 4 |u dkfz |
700 | 1 | _ | |a Hoffmeister, Michael |0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |b 5 |u dkfz |
700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 6 |e Last author |u dkfz |
773 | _ | _ | |a 10.1007/s00432-021-03865-3 |0 PERI:(DE-600)1459285-X |n 11 |p 3015-3028 |t Journal of cancer research and clinical oncology |v 148 |y 2022 |x 0171-5216 |
909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:177926 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)a4307287511137778efe28e651f9f245 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
914 | 1 | _ | |y 2021 |
915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-01-31 |w ger |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-31 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-31 |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-31 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-17 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J CANCER RES CLIN : 2021 |d 2022-11-17 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-17 |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-17 |
915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-17 |
920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 0 |
920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 1 |
920 | 1 | _ | |0 I:(DE-He78)M110-20160331 |k M110 |l M110 Epidemiologisches Krebsregister Baden-Württemberg |x 2 |
920 | 1 | _ | |0 I:(DE-He78)C071-20160331 |k C071 |l C071 Cancer Survivorship |x 3 |
920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 4 |
920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 5 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)C120-20160331 |
980 | _ | _ | |a I:(DE-He78)C070-20160331 |
980 | _ | _ | |a I:(DE-He78)M110-20160331 |
980 | _ | _ | |a I:(DE-He78)C071-20160331 |
980 | _ | _ | |a I:(DE-He78)C020-20160331 |
980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|